Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of benralizumab in patients with severe asthma
jRCTs031190237Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in severe asthma and eosinophilic asthma (EA), sponsored by AstraZeneca. Primary endpoint: Change from baseline in ACQ-5 at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
severe asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCTs031190237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190237.